Showing results (1011-1020 of 1,192) with videos related to
Sort By:
Pageof 120
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.Blood Advances|August 23, 2021
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosisNaveen Pemmaraju, Bing Z Carter, Prithviraj Bose, et al.Cancer|May 5, 2016
The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemiaJessica R Galloway-Peña, Daniel P Smith, Pranoti Sahasrabhojane, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisJohn Koreth, Joseph Pidala, Waleska S Perez, et al.Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.Blood|June 11, 2021
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaTomoyuki Tanaka, Kiyomi Morita, Sanam Loghavi, et al.American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.Pageof 120